Press release
Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2031 - Leading Companies are AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd.
Homozygous Familial Hypercholesterolemia Market
Homozygous Familial Hypercholesterolemia Market is thoroughly examined in the DataM Intelligence study, offering a comprehensive analysis supported by robust statistics, historical data, and actionable insights. The report evaluates key industry players, analyzing their product portfolios, pricing strategies, financial performance, and expansion efforts. It provides a clear understanding of market dynamics, competitive positioning, and anticipated trends shaping the future of the industry.
Get a Premium Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/homozygous-familial-hypercholesterolemia-market?rk
Rising Cardiovascular Disease Burden to Propel Homozygous Familial Hypercholesterolemia (HoFH) Market Growth
The increasing prevalence of cardiovascular diseases (CVDs) is a key factor driving the growth of the homozygous familial hypercholesterolemia (HoFH) market. HoFH is marked by extremely high LDL-C levels and significantly elevated risks of cardiovascular complications such as heart attacks and strokes. As awareness of the condition improves, early diagnosis and proactive treatment are gaining traction, boosting demand for effective HoFH therapies.
For example, the Centers for Disease Control and Prevention (CDC) reported in 2023 that heart disease remains one of the leading causes of death in the United States. Every 40 seconds, someone in the U.S. experiences a heart attack, totaling approximately 805,000 incidents annually. Coronary heart disease alone was responsible for 375,476 deaths in 2021. As cardiovascular health concerns continue to rise, the need for targeted HoFH treatments is expected to grow correspondingly over the forecast period.
List of the Key Players in the Homozygous Familial Hypercholesterolemia Market:
AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare, Changzhou Pharmaceutical Factory, Regeneron Pharmaceuticals, Inc., Amryt Pharma plc, Amgen Inc., Organon, Global Inc., CMP Pharma.
Homozygous Familial Hypercholesterolemia Industry Development:
Evkeeza Receives FDA Approval Expansion for Pediatric HoFH Patients
On March 22, 2023, Regeneron Pharmaceuticals, Inc. announced that the U.S. FDA has expanded the indication for Evkeeza (evinacumab-dgnb) to include children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering therapies. Evkeeza is now the first approved angiopoietin-like 3 (ANGPTL3) inhibitor for use in this young age group, offering a vital treatment option to help lower dangerously high LDL-C levels associated with HoFH.
Research Methodology
Our research methodology combines both qualitative and quantitative approaches to provide you with a thorough market analysis. We begin by gathering data from trusted industry reports and databases (secondary research), followed by primary research through surveys and interviews with key experts. We then apply advanced statistical tools to analyze the data, uncover trends, and assess market dynamics. Additionally, we use market segmentation and Porter's Five Forces analysis to evaluate competition. This approach ensures that the insights we provide are reliable, actionable, and tailored to support your decision-making process.
Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/homozygous-familial-hypercholesterolemia-market
Segment Covered in the Homozygous Familial Hypercholesterolemia Market:
By Drug Class: Statins, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, MTP Inhibitors, ANGPTL3 Inhibitors.
By Route of Administration: Oral, Parenteral, Nasal.
By Technology: CRISPR-Cas9, RNA Interference, Nanoparticle-Based Therapies.
By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies.
This Report Covers:
✔ Go-to-market Strategy.
✔ Neutral perspective on the market performance.
✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, Market Access, and other significant analysis, as well as development status.
✔Customized regional/country reports as per request and country level analysis.
✔ Potential & niche segments and regions exhibiting promising growth covered.
✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Regional Analysis for Homozygous Familial Hypercholesterolemia Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Top-down and bottom-up approach for regional analysis
➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.
➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market
Frequently asked questions:
➠ What is the global sales value, production value, consumption value, import and export of Homozygous Familial Hypercholesterolemia market?
➠ Who are the global key manufacturers of the Homozygous Familial Hypercholesterolemia Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?
➠ What are the Homozygous Familial Hypercholesterolemia market opportunities and threats faced by the vendors in the global Homozygous Familial Hypercholesterolemia Industry?
➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?
➠ What focused approach and constraints are holding the Homozygous Familial Hypercholesterolemia market?
➠ What are the different sales, marketing, and distribution channels in the global industry?
Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2031 - Leading Companies are AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd. here
News-ID: 4030633 • Views: …
More Releases from DataM Intelligence 4market Research LLP
Voice Assistant Market to Hit US$14.20 Billion by 2032, Driven by AI and IoT Exp …
According to DataM Intelligence, the voice assistant market was valued at US$ 2.73 billion in 2024 and is projected to reach US$ 14.20 billion by 2032, growing at a CAGR of 22.89% during the forecast period (2025-2032). Growth is primarily driven by the proliferation of smart devices, expanding IoT ecosystems, and the shift toward voice-based human-machine interfaces. The hardware segment, led by smart speakers and voice-enabled devices, currently dominates the…
North America Spatial Computing Market to Hit $260.8 Billion by 2032, Driven by …
According to DataM Intelligence, the North America spatial computing market size reached US$ 58,772.07 million in 2024 and is projected to surge to US$ 260,839.20 million by 2032, representing a robust CAGR of 20.9% during the forecast period (2025-2032). Several factors are driving this strong growth. The increasing adoption of immersive technologies (AR/VR/MR) across verticals such as healthcare, manufacturing, retail, and education is unlocking new applications. Moreover, advancements in connectivity…
Pharmaceutical Drying Equipment Market to Hit $10.35 Billion by 2033 - Driven by …
According to DataM Intelligence, the pharmaceutical drying equipment market reached US$ 5.45 billion in 2023, increased to US$ 5.78 billion in 2024, and is projected to reach US$ 10.35 billion by 2033, growing at a CAGR of 6.7% during the forecast period (2025-2033). Market growth is propelled by the rapid expansion of the pharmaceutical and biopharmaceutical sectors, technological innovations in drying systems, and the rise in outsourcing of drug manufacturing…
Triple Negative Breast Cancer Market Driven by Rising Cases and Immunotherapy Ad …
According to DataM Intelligence, the Triple Negative Breast Cancer Treatment Market reached approximately US$ 0.95 billion in 2023 and is projected to reach US$ 1.66 billion by 2033, growing at a CAGR of around 6.6% during the forecast period (2025-2033). The market growth is driven by the rising global incidence of breast cancer, the aggressive nature of TNBC, and rapid advancements in immunotherapy and antibody-drug conjugates (ADCs).
Key market growth drivers…
More Releases for Homozygous
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Homozygous Familial Hypercholesterolemia (HoFH) Market Massive Growth opportunit …
Introduction
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic lipid disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels from birth, often exceeding 500 mg/dL. Caused by mutations in both alleles of the LDLR, APOB, or PCSK9 genes, HoFH leads to early-onset atherosclerosis, cardiovascular disease, and premature mortality if untreated.
Historically, management relied on lipid-lowering agents, LDL apheresis, and lifestyle modifications. However, the last decade has witnessed a paradigm shift with…
Homozygous Familial Hypercholesterolemia Market 2025 | Market Growth, Genetic Sc …
Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2030 growing with a CAGR of 2.5% during the forecast period 2023-2030, according to DataM Intelligence research report, as per DataM intelligence research report.
Homozygous Familial Hypercholesterolemia Market: Recent Industry Developments
United States
✅ Regeneron announced the FDA extension of Evkeeza use to children aged 5-11 with HoFH, making it the first ANGPTL3 inhibitor…
New Syndrome: seemingly unrelated symptoms have a common cause in patients with …
The International H63D Mutation Research Consortium www.h63d-syndrome.org has announced the discovery of "Typ-2 H63D Syndrome", a genetic disease caused by a homozygous mutation of the HFE gene H63D. The research work, which spanned 12 years, uncovered that the mutation is responsible for a wide range of symptoms due to micro-inflammations, which can be challenging to diagnose without the proper knowledge and testing.
While classic Typ-1 H63D Syndrome is a rare disorder…
Latest Homozygous Familial Hypercholesterolemia Treatment Market Research | Comp …
Homozygous Familial Hypercholesterolemia Treatment Market
Market Strides has added a new report titled, “Global Homozygous Familial Hypercholesterolemia Treatment Market Professional Report 2027” to its vast repository of research reports. This is a comprehensive report focused on the current and future prospects of the Global Homozygous Familial Hypercholesterolemia Treatment Market. The report also mentions the impact of the coronavirus pandemic on the market. Furthermore, the study includes the steps the leading industry…
Homozygous Familial Hypercholesterolemia Treatment Market Size - Technological A …
Up Market Research (UMR) has published a latest market research report on Global Homozygous Familial Hypercholesterolemia Treatment Market. The global report is prepared in collaboration with the leading industry experts and dedicated research analyst team to provide an enterprise with in-depth market insights and help them to take crucial business decisions. This report covers current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.
The…
